Stefania Sartini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6066816/publications.pdf

Version: 2024-02-01

46	1,530	279487	315357
papers	citations	23 h-index	38 g-index

48	48	48	2376
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oxy-imino saccharidic derivatives as a new structural class of aldose reductase inhibitors endowed with anti-oxidant activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1194-1205.	2.5	5
2	Imidazo[1,2-a]pyridine Derivatives as Aldehyde Dehydrogenase Inhibitors: Novel Chemotypes to Target Glioblastoma Stem Cells. Journal of Medicinal Chemistry, 2020, 63, 4603-4616.	2.9	38
3	Synthetic mycomelanin thin films as emergent bio-inspired interfaces controlling the fate of embryonic stem cells. Journal of Materials Chemistry B, 2020, 8, 4412-4418.	2.9	17
4	Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation. Scientific Reports, 2019, 9, 9943.	1.6	4
5	pH-Responsive Carboxymethylcellulose Nanoparticles for 68Ga-WBC Labeling in PET Imaging. Polymers, 2019, 11, 1615.	2.0	9
6	Synthesis and investigation of polyhydroxylated pyrrolidine derivatives as novel chemotypes showing dual activity as glucosidase and aldose reductase inhibitors. Bioorganic Chemistry, 2019, 92, 103298.	2.0	13
7	Combined Use of Scanning Electron Microscopyâ€“Energy-Dispersive X-ray Spectroscopy and Fourier Transform Infrared Imaging Coupled with Principal Component Analysis in the Study of Ancient Egyptian Papyri. ACS Omega, 2019, 4, 22041-22047.	1.6	7
8	Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors. European Journal of Medicinal Chemistry, 2018, 150, 491-505.	2.6	13
9	Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors. Cell Chemical Biology, 2018, 25, 1414-1418.e3.	2.5	16
10	Copperâ€Catalyzed Recyclable Synthesis of (Z)â€3â€Alkylideneisoindolinones by Cycloisomerization of 2â€Alkynylbenzamides in Ionic Liquids. ChemistrySelect, 2017, 2, 894-899.	0.7	17
11	Cyclodextrin-based nanosponges for the targeted delivery of the anti-restenotic agent DB103: A novel opportunity for the local therapy of vessels wall subjected to percutaneous intervention. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 117, 276-285.	2.0	21
12	N -(Aroyl)- N -(arylmethyloxy)-Î±-alanines: Selective inhibitors of aldose reductase. Bioorganic and Medicinal Chemistry, 2017, 25, 3068-3076.	1.4	13
13	Synthesis and Functional Evaluation of Novel Aldose Reductase Inhibitors Bearing a Spirobenzopyran Scaffold. Open Medicinal Chemistry Journal, 2017, 11, 9-23.	0.9	2
14	Nanostructured ultra-thin patches for ultrasound-modulated delivery of anti-restenotic drug. International Journal of Nanomedicine, 2016, 11, 69.	3.3	30
15	A Series of COXâ€2 Inhibitors Endowed with NOâ€Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis. ChemMedChem, 2016, 11, 1804-1811.	1.6	6
16	FOXD1â€“ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells. Cancer Research, 2016, 76, 7219-7230.	0.4	120
17	1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions. Journal of Medicinal Chemistry, 2016, 59, 6547-6552.	2.9	20
18	Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer. Mini-Reviews in Medicinal Chemistry, 2015, 16, 86-93.	1.1	17

#	Article	IF	Citations
19	Synthesis, biological evaluation and docking analysis of a new series of methylsulfonyl and sulfamoyl acetamides and ethyl acetates as potent COX-2 inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 810-820.	1.4	21
20	Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2. European Journal of Medicinal Chemistry, 2015, 103, 29-43.	2.6	17
21	Synthetic analogues of flavonoids with improved activity against platelet activation and aggregation as novel prototypes of food supplements. Food Chemistry, 2015, 175, 494-499.	4.2	15
22	CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo. Molecular and Cellular Endocrinology, 2014, 393, 56-64.	1.6	21
23	CLM3, a Multitarget Tyrosine Kinase Inhibitor With Antiangiogenic Properties, Is Active Against Primary Anaplastic Thyroid Cancer In Vitro and In Vivo. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E572-E581.	1.8	46
24	A novel 2,3-diphenyl-4H-pyrido[1,2-a]pyrimidin-4-one derivative inhibits endothelial cell dysfunction and smooth muscle cell proliferation/activation. European Journal of Medicinal Chemistry, 2014, 72, 102-109.	2.6	18
25	Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies.. Journal of Medicinal Chemistry, 2014, 57, 1225-1235.	2.9	18
26	PMMA/Polysaccharides Nanofilm Loaded with Adenosine Deaminase Inhibitor for Targeted Anti-inflammatory Drug Delivery. Langmuir, 2013, 29, 13190-13197.	1.6	32
27	Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). European Journal of Medicinal Chemistry, 2013, 63, 765-781.	2.6	46
28	A New Approach to Control the Enigmatic Activity of Aldose Reductase. PLoS ONE, 2013, 8, e74076.	1.1	39
29	Benzofuroxane Derivatives as Multi-Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling Studies. Journal of Medicinal Chemistry, 2012, 55, 10523-10531.	2.9	24
30	Sampling protein motion and solvent effect during ligand binding. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1467-1472.	3.3	100
31	CLM94, a Novel Cyclic Amide with Anti-VEGFR-2 and Antiangiogenic Properties, Is Active against Primary Anaplastic Thyroid Cancer in Vitro and in Vivo. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E528-E536.	1.8	49
32	Progresses in the pursuit of aldose reductase inhibitors: The structure-based lead optimization step. European Journal of Medicinal Chemistry, 2012, 51, 216-226.	2.6	41
33	Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies. Journal of Medicinal Chemistry, 2011, 54, 1401-1420.	2.9	27
34	Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells. Biochemical Pharmacology, 2011, 81, 1309-1316.	2.0	26
35	Synthesis and Biological Evaluation of 2â€²â€Oxoâ€2,3â€dihydroâ€3â€²Hâ€• spiro[chromeneâ€4,5â€²â€{1,3]oxazolidin]â€3â€²yl]acetic Acid Derivatives as Aldose Reductase Inhibitors. Archiv Der Pharmazie, 2011, 344, 372-385.	2.1	21
36	Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications. European Journal of Medicinal Chemistry, 2011, 46, 2797-2806.	2.6	94

#	Article	IF	Citations
37	Novel Pyrazolopyrimidine Derivatives as Tyrosine Kinase Inhibitors with Antitumoral Activity in Vitro and in Vivo in Papillary Dedifferentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E288-E296.	1.8	71
38	Anti-ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non-diabetic rat hearts. Journal of Pharmacy and Pharmacology, 2010, 62, 107-113.	1.2	6
39	Pursuing Aldose Reductase Inhibitors through in Situ Cross-Docking and Similarity-Based Virtual Screening. Journal of Medicinal Chemistry, 2009, 52, 5578-5581.	2.9	36
40	Computational Studies of Epidermal Growth Factor Receptor: Docking Reliability, Three-Dimensional Quantitative Structureâ"Activity Relationship Analysis, and Virtual Screening Studies. Journal of Medicinal Chemistry, 2009, 52, 964-975.	2.9	34
41	Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one Ring System as a Useful Template To Obtain Potent Adenosine Deaminase Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 1681-1692.	2.9	44
42	Acetic Acid Aldose Reductase Inhibitors Bearing a Five-Membered Heterocyclic Core with Potent Topical Activity in a Visual Impairment Rat Model. Journal of Medicinal Chemistry, 2008, 51, 3182-3193.	2.9	47
43	Evidence for a Novel Binding Site Conformer of Aldose Reductase in Ligand-Bound Stateâ€. Journal of Molecular Biology, 2007, 369, 186-197.	2.0	33
44	Pyrido[1,2-a]pyrimidin-4-one Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors Exhibiting Antioxidant Activity. Journal of Medicinal Chemistry, 2007, 50, 4917-4927.	2.9	130
45	How Reliable Are Current Docking Approaches for Structure-Based Drug Design? Lessons from Aldose Reductase. Angewandte Chemie - International Edition, 2007, 46, 3575-3578.	7.2	53
46	Naphtho[1,2-d]isothiazole Acetic Acid Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 6897-6907.	2.9	53